Real-world data support the use of the MammaPrint index as a predictor of neoadjuvant chemosensitivity in patients with hormone receptor–positive, HER2-negative early-stage breast cancer.
Adjuvant ado-trastuzumab emtansine continued to improve overall survival and invasive disease-free survival vs trastuzumab after 8.4 years of follow-up in patients with HER2-positive early breast cancer and residual invasive disease following neoadjuvant therapy enrolled in the phase 3 KATHERINE trial.